Regeneron Pharmaceuticals REGN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's business segments — R&D?
- Regeneron Pharmaceuticals (REGN) reported business segments — R&D of $1.54B in Q1 2026.
- How has Regeneron Pharmaceuticals's business segments — R&D changed year-over-year?
- Regeneron Pharmaceuticals's business segments — R&D increased by 16.3% year-over-year, from $1.33B to $1.54B.
- What is the long-term trend for Regeneron Pharmaceuticals's business segments — R&D?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's business segments — R&D has grown at a 17.6% compound annual growth rate (CAGR), from $3.59B to $5.85B.
- What does business segments — R&D mean?
- This metric represents the total financial resources allocated to internal and collaborative research and development activities aimed at discovering and advancing new therapeutic candidates. It captures the operational investment required to sustain the company's drug pipeline, including clinical trials, preclinical studies, and drug discovery efforts. This figure is critical for assessing the company's commitment to long-term innovation and future revenue growth potential.